表紙
市場調查報告書

市場焦點:小細胞肺癌 (SCLC)

Market Spotlight: Small-Cell Lung Cancer (SCLC)

出版商 Datamonitor Healthcare 商品編碼 573562
出版日期 內容資訊 英文 64 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
市場焦點:小細胞肺癌 (SCLC) Market Spotlight: Small-Cell Lung Cancer (SCLC)
出版日期: 2019年10月25日內容資訊: 英文 64 Pages
簡介

本報告提供小細胞肺癌 (SCLC)的治療藥市場相關分析,提供疾病概要和患者數的轉變·預測,目前的主要治療方法及臨床實驗·認證情形,SCLC治療藥市場趨勢預測 (今後10年份),資本交易的動向,目前開發中的臨床實驗進展等調查。

分析的要點

疾病的背景情況

  • SCLC (小細胞肺癌)的詳細分類

治療方法

  • 化療
  • 放射治療
  • 手術
  • 一時緩和治療

流行病學

開發平台上的醫藥品

已上市醫藥品

  • 各國的認證情形

今後主要的動向

授權合約·資產收購交易

母專利

商機

臨床實驗形勢

  • 贊助商一覽:各狀態
  • 贊助商一覽:各期
  • 近幾年趨勢 (1件)

相關分析

  • 處方藥的資訊

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: DMKC0179721

This Market Spotlight report covers the small cell lung cancer market, comprising key pipeline and marketed drugs, recent events and analyst opinion, probability of success, clinical trials, upcoming and regulatory events, patent information, a 10-year disease incidence forecast, licensing and acquisition deals, and drug-specific revenue forecasts.

Key Takeaways

Datamonitor Healthcare estimates that in 2017, there were 310,300 incident cases of small cell lung cancer (SCLC) worldwide, and forecasts that number to increase to 339,500 incident cases by

2026. Northern America is estimated to have the highest disease incidence of SCLC (10.43 per 100,000 people), while Africa has the lowest incidence (0.47 per 100,000 people).

Approved drugs for SCLC focus on targets such as DNA, topoisomerase I, programmed death-1 receptor/programmed death ligands, and the immune system. These drugs are administered via the oral or intravenous routes.

The majority of industry-sponsored drugs in active clinical development for SCLC are in Phase II. Therapies in development for SCLC focus on a wide variety of targets. The majority of drugs in development for SCLC are administered via the intravenous route, with the remainder being oral, intratumoral, intramuscular, or subcutaneous formulations.

High-impact upcoming events for drugs in the SCLC space comprise topline Phase I/II trial results for Pegzilarginase, topline Phase II/III trial results for Unituxin, and topline Phase III trial results for Zepsyre and Keytruda.

The overall likelihood of approval of a Phase I solid tumors asset is 5.5%, and the average probability a drug advances from Phase III is 39.9%. Drugs, on average, take 9.5 years from Phase I to approval, compared to 9.3 years in the overall oncology space.

There have been 14 licensing and asset acquisition deals involving SCLC drugs during 2014-19. The largest deal was the $356m licensing agreement made in 2017 between CytRx and NantCell for the exclusive rights to develop and market aldoxorubicin.

The distribution of clinical trials across Phase I-IV indicates that the vast majority of trials for SCLC have been in the early and mid-phases of development, with 89% of trials in Phase I-II, and only 11% in Phase III-IV.

The US has a substantial lead in the number of SCLC clinical trials globally. The UK leads the major EU markets, while Japan has the top spot in Asia.

Clinical trial activity in the SCLC space is dominated by completed trials. GlaxoSmithKline and Pfizer have the highest number of completed clinical trials for SCLC, with 42 and 41 trials, respectively.

Pfizer leads industry sponsors with the highest overall number of clinical trials for SCLC, followed by GlaxoSmithKline and BristolMyers Squibb.

TABLE OF CONTENTS

OVERVIEW

KEY TAKEAWAYS

DISEASE BACKGROUND

TREATMENT

  • Chemotherapy
  • Radiotherapy
  • Immunotherapy
  • Surgery
  • Palliative procedures

EPIDEMIOLOGY

MARKETED DRUGS

PIPELINE DRUGS

RECENT EVENTS AND ANALYST OPINION

  • HLX10 for SCLC (September 12, 2019)
  • Onivyde for SCLC (September 8, 2019)
  • Imfinzi for SCLC (June 27, 2019)
  • Zepsyre for SCLC (June 1, 2019)
  • Sacituzumab Govitecan for SCLC (April 29, 2019)
  • Opdivo for SCLC (April 11, 2019)
  • Keytruda for SCLC (April 1, 2019)
  • Zepsyre for SCLC (March 25, 2019)
  • Beleodaq for SCLC (January 17, 2019)
  • Rova-T for SCLC (December 5, 2018)
  • Opdivo for SCLC (November 26, 2018)
  • Trilaciclib for SCLC (November 26, 2018)
  • Trilaciclib for SCLC (October 21, 2018)
  • Opdivo for SCLC (October 12, 2018)
  • Tecentriq for SCLC (September 25, 2018)
  • Opdivo for SCLC (August 16, 2018)

KEY UPCOMING EVENTS

KEY REGULATORY EVENTS

  • Tecentriq Nod For SCLC
  • CHMP Recommendation For Roche's Tecentriq In Expanded Patient Population
  • Merck's Keytruda Nabs First SCLC Approval
  • France OKs Early Access To Tecentriq For SCLC Pending EU Approval

PROBABILITY OF SUCCESS

LICENSING AND ASSET ACQUISITION DEALS

  • Luye Licenses Novel Oncology Drug From Pharmamar

PARENT PATENTS

REVENUE OPPORTUNITY

CLINICAL TRIAL LANDSCAPE

  • Sponsors by status
  • Sponsors by phase
  • Recent events

BIBLIOGRAPHY

  • Prescription information

APPENDIX

LIST OF FIGURES

  • 14 Figure 1: Trends in incident cases of SCLC, 2017-26
  • 19 Figure 2: Overview of pipeline drugs for SCLC in the US
  • 19 Figure 3: Pipeline drugs for SCLC, by company
  • 20 Figure 4: Pipeline drugs for SCLC, by drug type
  • 20 Figure 5: Pipeline drugs for SCLC, by classification
  • 28 Figure 6: Onivyde for SCLC (September 8, 2019): Phase II/III - RESILIENT
  • 30 Figure 7: Imfinzi for SCLC (June 27, 2019): Phase III - CASPIAN
  • 32 Figure 8: Zepsyre for SCLC (June 1, 2019): Phase II - Solid Tumors (Relapsed SCLC; EU/US)
  • 35 Figure 9: Opdivo for SCLC (April 11, 2019): Phase III - CheckMate-451 (Maintenance)
  • 37 Figure 10: Keytruda for SCLC (April 1, 2019): Phase Ib - KEYNOTE-028 (PD-L1 Positive Tumors), Phase II - KEYNOTE-158
  • 42 Figure 11: Opdivo for SCLC (November 26, 2018): Phase III - CheckMate-451 (Maintenance)
  • 44 Figure 12: Trilaciclib for SCLC (November 26, 2018): Phase II - w/Tecentriq+Chemotherapy
  • 46 Figure 13: Trilaciclib for SCLC (October 21, 2018): Phase Ib/IIa - w/Etoposide/Carboplatin (02)
  • 48 Figure 14: Opdivo for SCLC (October 12, 2018): Phase III - CheckMate 331
  • 49 Figure 15: Tecentriq for SCLC (September 25, 2018): Phase I/III - IMpower133 (Carboplatin + Etoposide, ES-SCLC)
  • 51 Figure 16: Key upcoming events in SCLC
  • 53 Figure 17: Probability of success in the SCLC pipeline
  • 54 Figure 18: Licensing and asset acquisition deals in SCLC, 2014-19
  • 55 Figure 19: Parent patents in SCLC
  • 57 Figure 20: Clinical trials in SCLC
  • 57 Figure 21: Top 10 drugs for clinical trials in SCLC
  • 58 Figure 22: Top 10 companies for clinical trials in SCLC
  • 58 Figure 23: Trial locations in SCLC
  • 59 Figure 24: SCLC trials status
  • 60 Figure 25: SCLC trial sponsors, by phase

LIST OF TABLES

  • 13 Table 1: Incident cases of SCLC, 2017-26
  • 15 Table 2: Incidence rates of SCLC, 2017-26
  • 17 Table 3: Marketed drugs for SCLC
  • 21 Table 4: Pipeline drugs for SCLC in the US
  • 26 Table 5: HLX10 for SCLC (September 12, 2019)
  • 27 Table 6: Onivyde for SCLC (September 8, 2019)
  • 29 Table 7: Imfinzi for SCLC (June 27, 2019)
  • 30 Table 8: Zepsyre for SCLC (June 1, 2019)
  • 33 Table 9: Sacituzumab Govitecan for SCLC (April 29, 2019)
  • 34 Table 10: Opdivo for SCLC (April 11, 2019)
  • 36 Table 11: Keytruda for SCLC (April 1, 2019)
  • 38 Table 12: Zepsyre for SCLC (March 25, 2019)
  • 39 Table 13: Beleodaq for SCLC (January 17, 2019)
  • 40 Table 14: Rova-T for SCLC (December 5, 2018)
  • 41 Table 15: Opdivo for SCLC (November 26, 2018)
  • 42 Table 16: Trilaciclib for SCLC (November 26, 2018)
  • 45 Table 17: Trilaciclib for SCLC (October 21, 2018)
  • 47 Table 18: Opdivo for SCLC (October 12, 2018)
  • 48 Table 19: Tecentriq for SCLC (September 25, 2018)
  • 50 Table 20: Opdivo for SCLC (August 16, 2018)
  • 56 Table 21: Historical global sales, by drug ($m), 2014-18
  • 56 Table 22: Forecasted global sales, by drug ($m), 2019-23
Back to Top